Phillip Febbo is a distinguished medical professional and researcher who currently serves as the Chief Scientific and Chief Medical Officer at Veracyte, Inc. Dr. Febbo earned his medical degree from the University of Pennsylvania School of Medicine and completed his residency in internal medicine at the Massachusetts General Hospital. He furthered his training with a fellowship in medical oncology at the Dana-Farber Cancer Institute, where he also conducted research in cancer genomics. Prior to joining Veracyte, Dr. Febbo held significant roles at Genomic Health, where he was the Chief Medical Officer and Senior Vice President, and at UCSF, where he was a Professor of Medicine and Urology. At Veracyte, Dr. Febbo plays a pivotal role in driving the company's mission to improve patient care through advanced diagnostics. His leadership is instrumental in the development and commercialization of Veracyte's innovative tests, which help physicians make more informed treatment decisions for patients with cancer and other diseases. Under his guidance, Veracyte has expanded its portfolio of diagnostic tests, including the Afirma and Percepta tests for thyroid and lung cancer, respectively. Dr. Febbo's expertise in molecular diagnostics and oncology has been crucial in establishing Veracyte as a leader in the field of precision medicine. Dr. Febbo's contributions to the field extend beyond his work at Veracyte. He has authored numerous peer-reviewed publications and has been actively involved in several professional organizations, including the American Society of Clinical Oncology. His research has focused on the molecular mechanisms of cancer, particularly prostate cancer, and he has been a strong advocate for the integration of genomic data into clinical practice. Dr. Febbo's dedication to advancing medical science and improving patient outcomes has earned him recognition as a thought leader in the oncology and diagnostics communities.